BIXT (Mkap $27 M) HEIß & Unbekannter Coronavirus Play


ISIN: US09075D1028 | Symbol: BIXT
0,310
$
21:57:22
Nasdaq OTC
+6,90 %
+0,020 USD

Beitrag schreiben

Begriffe und/oder Benutzer

 

UNBEKANNTE Coronavirus Aktie die eventuell auch durch die Decke gehen könnte . Und nicht vergessen HIGH RISK .

Bioxytran (BIXT) --Marktkap $27 M --Aktienanzahl 86 Million davon hält Management allein 73 million Aktien


Bioxytran Inc. Discusses the Use of BXT-25 as a Late Stage Treatment for the Coronavirus
https://finance.yahoo.com/news/bioxytran-inc-discusses-bxt-2…


Bioxytran Seeking Partners for Late Stage Treatment of Wuhan Coronavirus using BXT-25
https://www.globenewswire.com/news-release/2020/02/05/198013…

BXT-25 has the potential to treat late stage acute respiratory distress syndrome (ARDS) which is the leading cause of death in coronavirus patients.


Insiders:
Platt (David)...43.0M
Soderquist (Ola)...21.1M
Offer (Binder)..8.7M
Antwort auf Beitrag Nr.: 62.808.128 von Biohero am 27.02.20 15:33:10Könnte sehr schnell die $1 marke knacken

Bioxytran | 0,315 $
Antwort auf Beitrag Nr.: 62.808.581 von Biohero am 27.02.20 15:59:14sieht interessant, bin gut dabei ;-)
Bioxytran | 0,350 $
Antwort auf Beitrag Nr.: 62.808.812 von julfi am 27.02.20 16:12:06so liebe ich das hehehe
Bioxytran | 0,350 $
Antwort auf Beitrag Nr.: 62.808.812 von julfi am 27.02.20 16:12:06
Zitat von julfi: sieht interessant, bin gut dabei ;-)


Wie ich es hasse, kann solche Aktien auf Swissquote nicht kaufen. Immer wird der Auftrag abgelehnt...
Bioxytran | 0,350 $
Antwort auf Beitrag Nr.: 62.809.253 von BTRRR am 27.02.20 16:35:02OTC Werte handelt Swissquote, wie die Grossbanken, nicht mehr

Grüsse aus der Schweiz

Zubi
Bioxytran | 0,570 $
Neuer Artikel draußen ...

Top Coronavirus Stocks backed by Scientific Evidence ... Posted on February 27, 2020
https://insiderfinancial.com/top-coronavirus-stocks-backed-b…

"Just recently Bioxytran Inc. (OTCMKT: BIXT) announced it was seeking to partner with a drug company to treat COVID-19 using its lead compound BXT-25. Bioxytran is developing an oxygen transport molecule that 5000 times smaller than a red blood cell. It’s molecule is based off of Hemopure which is an FDA approved blood substitute for veterinary use. The drug is thought to be safe and is designed to get rid of the Nitric Oxygen scavenging which effected the approval trajectory of Hemopure. The drug is a product of over 30 years and $500 million of drug development. As an oxygen carrier it can treat literally any disease including ARDS and stroke. In ARDS the theoretical mechanism is that BXT-25 would be part of the blood plasma that leaks out into the lungs getting much closer to the air so that it is able to capture the oxygen and recirculate it. Unless they are able to get a quick approval and funding this preclinical asset may be too late to join the fight regardless of the vastness of their platform technology to deliver oxygen without a hypobaric chamber."
Bioxytran | 0,460 $


Beitrag zu dieser Diskussion schreiben